Apellis Pharmaceuticals, Inc. $APLS Shares Acquired by EFG Asset Management North America Corp.

EFG Asset Management North America Corp. increased its position in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) by 48.0% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 155,399 shares of the company’s stock after buying an additional 50,375 shares during the quarter. EFG Asset Management North America Corp.’s holdings in Apellis Pharmaceuticals were worth $3,517,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in APLS. Osaic Holdings Inc. grew its position in Apellis Pharmaceuticals by 141.2% in the second quarter. Osaic Holdings Inc. now owns 2,682 shares of the company’s stock worth $47,000 after acquiring an additional 1,570 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Apellis Pharmaceuticals by 15.6% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,855 shares of the company’s stock valued at $84,000 after purchasing an additional 655 shares during the last quarter. EverSource Wealth Advisors LLC grew its holdings in shares of Apellis Pharmaceuticals by 338.5% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 5,429 shares of the company’s stock worth $94,000 after purchasing an additional 4,191 shares during the period. Headlands Technologies LLC grew its holdings in shares of Apellis Pharmaceuticals by 748.8% during the 2nd quarter. Headlands Technologies LLC now owns 6,892 shares of the company’s stock worth $119,000 after purchasing an additional 6,080 shares during the period. Finally, Amalgamated Bank raised its holdings in Apellis Pharmaceuticals by 12.0% in the 2nd quarter. Amalgamated Bank now owns 8,111 shares of the company’s stock valued at $140,000 after buying an additional 866 shares during the period. 96.29% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the stock. TD Cowen decreased their target price on shares of Apellis Pharmaceuticals from $50.00 to $45.00 and set a “buy” rating on the stock in a research report on Friday, October 31st. Bank of America upgraded shares of Apellis Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $28.00 price objective on the stock in a report on Wednesday, January 21st. Robert W. Baird increased their price objective on shares of Apellis Pharmaceuticals from $50.00 to $52.00 and gave the stock an “outperform” rating in a research report on Friday, October 31st. Cantor Fitzgerald cut their target price on Apellis Pharmaceuticals from $39.00 to $35.00 and set an “overweight” rating on the stock in a research report on Tuesday, January 13th. Finally, The Goldman Sachs Group restated a “sell” rating and set a $19.00 price target on shares of Apellis Pharmaceuticals in a research note on Monday, January 12th. Twelve research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Apellis Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $33.53.

Apellis Pharmaceuticals Trading Up 1.1%

NASDAQ:APLS opened at $21.99 on Tuesday. Apellis Pharmaceuticals, Inc. has a 12-month low of $16.10 and a 12-month high of $30.80. The firm has a market cap of $2.78 billion, a PE ratio of 70.94 and a beta of 0.31. The company has a current ratio of 3.54, a quick ratio of 3.10 and a debt-to-equity ratio of 0.90. The stock has a fifty day moving average price of $23.06 and a 200 day moving average price of $23.61.

Apellis Pharmaceuticals (NASDAQ:APLS) last issued its quarterly earnings results on Thursday, October 30th. The company reported $1.67 earnings per share for the quarter, topping the consensus estimate of $1.03 by $0.64. The company had revenue of $458.58 million for the quarter, compared to the consensus estimate of $364.58 million. Apellis Pharmaceuticals had a return on equity of 18.94% and a net margin of 4.43%.Apellis Pharmaceuticals’s revenue was up 133.0% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.46) EPS. Sell-side analysts anticipate that Apellis Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Insider Transactions at Apellis Pharmaceuticals

In other Apellis Pharmaceuticals news, insider Pascal Deschatelets sold 5,928 shares of the stock in a transaction that occurred on Thursday, January 22nd. The shares were sold at an average price of $21.77, for a total value of $129,052.56. Following the sale, the insider directly owned 1,151,382 shares of the company’s stock, valued at approximately $25,065,586.14. This represents a 0.51% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, insider Mark Jeffrey Delong sold 3,371 shares of Apellis Pharmaceuticals stock in a transaction on Thursday, January 22nd. The stock was sold at an average price of $21.77, for a total transaction of $73,386.67. Following the sale, the insider directly owned 78,353 shares of the company’s stock, valued at approximately $1,705,744.81. This trade represents a 4.12% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 125,169 shares of company stock valued at $2,700,681 over the last quarter. Insiders own 6.80% of the company’s stock.

Apellis Pharmaceuticals Profile

Apellis Pharmaceuticals, Inc, traded as NASDAQ:APLS, is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the complement cascade for the treatment of rare and debilitating diseases. The company’s research and development efforts center on modulating complement proteins to address a range of ophthalmologic, hematologic and renal conditions. Apellis leverages its proprietary compstatin technology platform to design targeted inhibitors intended to improve patient outcomes and quality of life.

The company’s lead marketed product, Syfovre (pegcetacoplan), is an intravitreal complement C3 inhibitor approved for geographic atrophy secondary to age-related macular degeneration, with ongoing investigations in other retinal disorders.